Floatz logo

Zanubrutinib

Lymphoma, Lymphoblastic

Sun Yat-sen UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Lymphoma, Lymphoblastic cohort.

Asset / SponsorPhaseRating
ASPARAGINASE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 4BBB
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BBB
Cytosin-Arabinosid
Johann Wolfgang Goethe University Hospital
Phase 4BB
VINBLASTINE
St. Jude Children's Research Hospital
Phase 2B
Teniposide
St. Jude Children's Research Hospital
Phase 2B
Theprubicin
Sun Yat-sen University
Phase 2CCC
ctd402 car t cell
BIOHENG THERAPEUTICS US LLC
Phase 1/2CCC

Same molecule, other indications

Zanubrutinib is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
splenic marginal zone lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
marginal zone lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →